Cancers | Free Full-Text | Molecular Targets for the Treatment of Metastatic Colorectal Cancer | HTML
Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan | BMC Cancer | Full Text
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group - Annals
KRAS Biomarker | Colorectal Cancer Alliance
Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study | BMJ Open
Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients | Nature Communications
Rare case of triple mutant (KRAS + NRAS + BRAF) metastatic colon adenocarcinoma | BMJ Case Reports
KRAS Biomarker | Colorectal Cancer Alliance
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon | Nature Genetics
Colon cancer biology: focus on epidermal growth factor (EGF) pathway... | Download Scientific Diagram
KRAS, NRAS, BRAF, HER2 and Microsatellite Instability in Metastatic Colorectal Cancer – Practical Implications for the Clinician | Semantic Scholar
Colorectal Cancer
Molecular Testing for Colon Cancer Falls Far Short of the Guidelines
ASCO Recommends Extended RAS Gene Testing in Metastatic Colorectal Cancer – OncoPrescribe
NRAS mutant E132K identified in young-onset sporadic colorectal cancer and the canonical mutants G12D and Q61K affect distinct oncogenic phenotypes | Scientific Reports
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis - The Lancet Oncology
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial - Annals of Oncology
KRAS, NRAS, and BRAF mutation prevalence, clinicopathological association, and their application in a predictive model in Mexican patients with metastatic colorectal cancer: A retrospective cohort study | PLOS ONE
Frontiers | Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers
Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations
Effect of KRAS and NRAS mutations on the prognosis of patients with synchronous metastatic colorectal cancer presenting with liver‑only and lung‑only metastases
Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan | BMC Cancer | Full Text
